June 25, 2014: Versant’s Inception plants its booming biotech startup model in Montreal.
See fiercebiotech.com for more.
June 24, 2014: Montreal - Versant Ventures Expands Canadian Operations with Launch of Inception Sciences in Montreal - Drug Discovery Engine to Create New Companies.
Versant Ventures, a global life sciences venture capital firm, continues its Canadian growth strategy with the launch of biopharmaceutical incubator Inception Sciences in Montreal. Versant, with Inception Sciences, will be working to launch new companies that can accelerate the commercialization of scientific research in the province of Quebec. Press Release:
June 24, 2014: Inception Sciences Appoints Clare Ozawa as Chief Operating Officer
San Diego, Calif. and Vancouver, Canada–Inception Sciences, a drug discovery incubator that launches new companies in collaboration with academia and pharmaceutical companies, today announced that Clare Ozawa, Ph.D. was named Chief Operating Officer.
Clare Ozawa joined Inception Sciences in January 2011 as founding Chief Business Officer. In her new role as COO, Clare will have overall responsibility for Inception’s global operations, including strategic business development, and oversight of Inception’s launch of a new site in Montreal, Canada. Press Release:
June 23, 2014: Tapping UCSF Invention, Roche and Versant Dive Into Myelin Repair
June 23, 2014: Roche announces partnership to discover novel disease-modifying therapies for multiple sclerosis.
Roche announced today that it has entered into an exclusive partnership with Inception Sciences, Inc., and Versant Ventures to create Inception 5, a new company dedicated to the research and development of novel small molecule remyelinating therapies for patients with multiple sclerosis. Press Release:
Nov. 18, 2013: Bayer HealthCare, Inception Sciences and Versant Ventures Join Forces to Develop Innovative Therapeutics for Retinal Eye Diseases.
Bayer HealthCare, Inception Sciences, Inc. and Versant Ventures will jointly conduct early research in the area of ophthalmology, in a newly created company called “Inception 4”. The goal of this new alliance is to develop treatment options, focused on a novel target and pathway, for patients with eye diseases, such as wet age-related macular degeneration and geographic atrophy.
Click here for more: Inception Sciences in the News